Mobile Marketing: It's Go Time

The sales reps are game, the HCPs are receptive and the mobile technology is ready. Rebecca Mayer Knutsen reports on the circumstances that have converged ...

Journal Ad Review: Back in the Mix

A few years ago medical publishers were approaching a cliff and the choices were simple: Evolve the business or fall over the edge. By having ...

How to Win an MM&M Award: 2015

You have fewer than six weeks to enter the MM&M Awards. No problem. Follow our checklist of Do's and Don'ts and tune in to our ...

Headliner: New Synta chief adds commercialization clout

Anne Whitaker, President and CEO, Synta Pharmaceuticals

Formulary Fireworks

In the wake of the high-profile showdown between Gilead and Express Scripts over the pricing of hepatitis-C drugs Sovaldi and Harvoni, the pharma/PBM balance of ...

Therapeutic Focus: Metabolic

Is this finally the year that anti-obesity drugs make the leap from niche curio to mainstream therapy? Frank Celia reports on the changing practitioner mind-set ...

Latest

Imbruvica eases AbbVie's patent worries

Imbruvica eases AbbVie's patent worries

AbbVie's $21-billion bid to acquire Pharmacyclics may insulate the drugmaker from the impact of impending Humira biosimilars.

Tufts: biosimilars will not be an instant hit

A study by the nonprofit research group found resistance to drug switching.

Accenture survey finds lacking alignment between pharma IT and marketing

The move toward digital will likely bring greater collaboration between CMOs and CIOs.

Eisai and Merck make cancer research pact

The drugmakers will explore combinations of Merck's Keytruda and Eisai's Lenvima and Halaven to treat certain cancers.

Five things for pharma marketers to know: Thursday, March 5

Five things for pharma marketers to know: Thursday, March 5

AbbVie nabs Pharmacyclics for $21 billion, Mallinckrodt makes a Pfizer-Hospira style acquisition, and the National Cancer Institute's director resigns

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

The FDA granted the drug Priority Review status just last week.

HCB Health acquires Topin & Associates

HCB Health acquires Topin & Associates

Austin-based HCB Health announced Tuesday its acquisition of Chicago indie agency Topin & Associates in an effort to push the borders of its client base.

Orexigen pleases shareholders, irks FDA

The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.

Haymarket Media acquires digital agency Group DCA

Haymarket Media acquires digital agency Group DCA

Haymarket purchased HCP-engagement specialist Group DCA and will operate the digital agency out of its custom medical communications division.

Five things for pharma marketers to know: Wednesday, March 4

Five things for pharma marketers to know: Wednesday, March 4

FDA adds new language to low-T drug labels; Afrezza's launch has a poor start, investors say; BMS acquires prostate-cancer vaccine in a deal worth $975 million.

Agency Spotlight


 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters